CA2412436C - Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury - Google Patents

Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury Download PDF

Info

Publication number
CA2412436C
CA2412436C CA2412436A CA2412436A CA2412436C CA 2412436 C CA2412436 C CA 2412436C CA 2412436 A CA2412436 A CA 2412436A CA 2412436 A CA2412436 A CA 2412436A CA 2412436 C CA2412436 C CA 2412436C
Authority
CA
Canada
Prior art keywords
cells
subject
tissue
human
endothelial progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2412436A
Other languages
English (en)
French (fr)
Other versions
CA2412436A1 (en
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Priority to CA2810249A priority Critical patent/CA2810249A1/en
Publication of CA2412436A1 publication Critical patent/CA2412436A1/en
Application granted granted Critical
Publication of CA2412436C publication Critical patent/CA2412436C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
CA2412436A 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury Expired - Lifetime CA2412436C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2810249A CA2810249A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58744100A 2000-06-05 2000-06-05
US09/587,441 2000-06-05
PCT/US2001/018399 WO2001094420A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2810249A Division CA2810249A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury

Publications (2)

Publication Number Publication Date
CA2412436A1 CA2412436A1 (en) 2001-12-13
CA2412436C true CA2412436C (en) 2013-05-21

Family

ID=24349821

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2412436A Expired - Lifetime CA2412436C (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
CA2810249A Abandoned CA2810249A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2810249A Abandoned CA2810249A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury

Country Status (7)

Country Link
US (6) US20040131585A1 (https=)
EP (2) EP2324839B1 (https=)
JP (3) JP5414958B2 (https=)
AU (1) AU2001275339A1 (https=)
CA (2) CA2412436C (https=)
MX (1) MXPA02012067A (https=)
WO (1) WO2001094420A1 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
EP1465983B1 (en) * 2001-12-21 2010-03-31 Immunex Corporation Endothelial stem cells, populations, methods of isolation and use thereof
JP2005528362A (ja) 2002-03-21 2005-09-22 ユニヴァーシティ オヴ フロリダ 血管新生の調節法
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2004052177A2 (en) * 2002-12-05 2004-06-24 Case Western Reserve University Cell-based therapies for ischemia
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
KR20060008870A (ko) * 2003-03-20 2006-01-27 게이이치 후쿠다 Ｇ-ｃｓｆ와 혈관 신생 작용을 갖는 인자의 병용
EP1632241A4 (en) * 2003-05-16 2009-07-22 Kyowa Hakko Kirin Co Ltd MEANS FOR THE PREVENTION AND / OR HEALING OF DISEASES IN CONNECTION WITH TISSUE DISORDER
DE10333901A1 (de) * 2003-07-21 2005-03-10 Transtissue Technologies Gmbh Verwendung von Chemokinen zur Rekrutierung von humanen mesenchymalen Vorläuferzellen zur Regeneration von Gelenkdefekten
EP1527785A1 (en) * 2003-10-27 2005-05-04 Ludwig-Maximilians-Universität München Use of G-CSF for treating ischemia
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
EP2946666B1 (en) 2004-04-30 2017-11-15 OrbusNeich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US20050265980A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
ATE423842T1 (de) * 2004-08-13 2009-03-15 Medtronic Inc Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung
EP1827494A4 (en) * 2004-11-18 2010-02-17 Wayne Franco COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
MY147516A (en) * 2005-11-07 2012-12-31 Amorcyte Inc Compositions and method of vascular injury repair cross-reference to related applications
EP1991664B1 (en) 2006-02-16 2018-03-28 Ospedale San Raffaele S.r.l. Skeletal muscle periangioblasts and cardiac mesangioblasts, method for isolation and uses thereof
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
RU2388425C2 (ru) * 2006-08-09 2010-05-10 Федеральное государственное учреждение Новосибирский научно-исследовательский институт патологии кровообращения имени акад. Е.Н. Мешалкина Федерального агентства по высокотехнологичной медицинской помощи Способ лазерного энграфтинга клеток
US20100034794A1 (en) * 2006-10-03 2010-02-11 Van Der Strate Barry W A Endothelial progenitor cell compositions and neovascularization
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
AU2008223817A1 (en) * 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
JP2010523496A (ja) 2007-03-30 2010-07-15 ザ クリーブランド クリニック ファウンデーション 虚血障害の治療方法
US8496926B2 (en) 2007-04-16 2013-07-30 Biocardia, Inc. Treatment for chronic myocardial infarction
US8012474B2 (en) * 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
KR101589442B1 (ko) * 2007-08-06 2016-02-01 녹손 파르마 아게 에스디에프-1 결합형 핵산 및 이의 용도
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
US8124071B2 (en) 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
WO2009073616A2 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
GB0818725D0 (en) 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition
CN102245189B (zh) * 2008-12-03 2015-06-17 阿莫塞特公司 改善梗死区灌注的组合物以及血管损伤修复方法
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
HRP20210334T1 (hr) * 2009-12-11 2021-04-02 Medregen, Llc Metode liječenja u kojima se primjenjuju mobilizatori matičnih stanica i imunosupresivna sredstva
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011082339A2 (en) * 2009-12-31 2011-07-07 Cedars-Sinai Medical Center Regeneration of, reestablishing function in and replacing microvasculature in organs and tissues
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
AR087363A1 (es) 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US20130231647A1 (en) * 2012-03-05 2013-09-05 BFM Group International GMBH Laser therapy for endogenously enhancing ventricular function
KR101540698B1 (ko) * 2012-10-05 2015-07-30 사회복지법인 삼성생명공익재단 허혈혈청을 포함하는 줄기세포 활성화 촉진용 조성물 및 줄기세포의 활성화 촉진 방법
AU2015256383B2 (en) 2014-05-08 2020-05-21 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
MX392743B (es) 2017-04-12 2025-03-12 Magenta Therapeutics Inc Antagonistas del receptor de hidrocarburo de arilo y sus usos.
WO2019032930A1 (en) 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111712262A (zh) 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
EP3735412B1 (en) 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
KR102056447B1 (ko) * 2018-03-16 2019-12-16 (주)메디노 신경줄기세포를 이용한 혈관형성 유도 방법
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107195A (en) * 1870-09-06 Improvement in sawing-machine
US5008284A (en) 1989-02-15 1991-04-16 E. R. Squibb & Sons, Inc. Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
AU651068B2 (en) * 1989-07-21 1994-07-14 Washington University Recombinantly produced human membrane cofactor protein (MCP)
EP0504257A4 (en) * 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
JP2697495B2 (ja) * 1991-06-19 1998-01-14 富士レビオ株式会社 アルデヒド誘導体
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
JPH07166906A (ja) * 1993-12-14 1995-06-27 Nissan Motor Co Ltd 燃料カットと点火時期変更による加速スリップ制御装置
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US6110889A (en) * 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
JP3866800B2 (ja) 1996-08-29 2007-01-10 東菱薬品工業株式会社 アポトーシス関連疾患の予防及び／又は治療薬
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
EP0897980A3 (en) * 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
EP1021737B1 (en) * 1997-10-06 2008-06-11 Acculase, Inc. Apparatus for ablating tissue
AU2559799A (en) * 1998-01-22 1999-08-09 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
CA2311729A1 (en) * 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
IL138075A0 (en) * 1998-02-27 2001-10-31 Univ Pennsylvania Vaccines, immunotherapeutics and methods for using the same
CA2322559C (en) * 1998-03-09 2012-07-17 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
US20020107196A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US20060057722A1 (en) * 1999-03-30 2006-03-16 Myocardial Therapeutics, Inc. Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
WO2000057922A1 (en) 1999-03-30 2000-10-05 Ran Kornowski Intramyocardial injection of autologous bone marrow
US20060051334A1 (en) * 1999-03-30 2006-03-09 Myocardial Therapeutics, Inc. Injection of bone marrow-derived conditioned medium for angiogenesis
JP5704780B2 (ja) 1999-08-13 2015-04-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 脈管形成因子の用量および心筋血流を改善するための投与方法
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1311547A2 (en) 2000-08-22 2003-05-21 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of cardiovascular conditions
WO2002020848A2 (en) * 2000-09-08 2002-03-14 The Regents Of The University Of California Gene and sequence variation associated with cancer
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
US20020094327A1 (en) 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004013158A2 (en) 2002-08-01 2004-02-12 Northwestern University MUTANTS OF IgE PROTEINS AND USES THEREOF
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP2069262A2 (en) * 2006-08-29 2009-06-17 Corning Incorporated High strength substantially non-microcracked cordierite honeycomb body and manufacturing method
US7959387B2 (en) 2007-10-03 2011-06-14 Kennametal Inc. Shrink fit sleeve for tool holder

Also Published As

Publication number Publication date
JP5710709B2 (ja) 2015-04-30
US20100209401A1 (en) 2010-08-19
JP2013063979A (ja) 2013-04-11
EP1290033B1 (en) 2012-10-31
US20060111290A1 (en) 2006-05-25
US7662392B2 (en) 2010-02-16
WO2001094420B1 (en) 2002-03-07
EP2324839B1 (en) 2017-08-09
JP5710574B2 (ja) 2015-04-30
US20080057069A1 (en) 2008-03-06
US9387234B2 (en) 2016-07-12
US8486416B2 (en) 2013-07-16
EP1290033A4 (en) 2004-12-08
US20090142296A1 (en) 2009-06-04
JP2004509847A (ja) 2004-04-02
WO2001094420A1 (en) 2001-12-13
JP5414958B2 (ja) 2014-02-12
CA2810249A1 (en) 2001-12-13
AU2001275339A1 (en) 2001-12-17
US8153113B2 (en) 2012-04-10
US20150150943A1 (en) 2015-06-04
MXPA02012067A (es) 2004-08-19
JP2014001221A (ja) 2014-01-09
US20040131585A1 (en) 2004-07-08
EP1290033A1 (en) 2003-03-12
EP2324839A1 (en) 2011-05-25
CA2412436A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
CA2412436C (en) Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
Kocher et al. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines
Kocher et al. Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function
Rüster et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells
CN100379751C (zh) 通过诱导新血管形成使内生性心肌组织再生
Van Dijk et al. Reduction of infarct size by intravenous injection of uncultured adipose derived stromal cells in a rat model is dependent on the time point of application
Mazo et al. Transplantation of mesenchymal stem cells exerts a greater long-term effect than bone marrow mononuclear cells in a chronic myocardial infarction model in rat
Itescu et al. Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function
Itescu et al. Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function
Itescu et al. Adult bone marrow-derived angioblasts for improvement of cardiomyocyte function after myocardial ischemia
Verdugo et al. Greater Long-Term Effect Than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Model in Rat Manuel Mazo,* Juan Jose Gavira,† Gloria Abizanda,* Cristina Moreno,‡ Margarita Ecay, § Mario Soriano,# Pablo Aranda,* Marıa Collantes, § Eduardo Alegrıa,† Juana Merino,‡ IvanPenuelas
Lapid et al. Mobilization of Hematopoietic Stem and Progenitor Cells

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210607